中心动脉压与肱动脉压关系的探讨

目的研究中心动脉压与外周动脉压之间的关系及影响因素。方法 100例进行冠状动脉造影检查的患者,术中使用动脉导管直接测压法测量中心动脉压及肱动脉压,分析二者之间关系及年龄和高血压对中心动脉压与肱动脉压问的相关性的影响。结果 100例患者肱动脉收缩压显著高于升主动脉收缩压[(132±22)mmHg比(128±21)mm Hg,P=0.0001],肱动脉舒张压与升主动脉舒张压差异无统计学意义[(66±11)mm Hg比(67±11)mm Hg,P0.05],在老年组、非老年组及各年龄组肱动脉脉压均高于升主动脉脉压(P=0.0001);老年组的升主动脉及肱动脉脉压显著高于非老年组[(72±17)mm Hg比(52±14)mm Hg,(77±18)mm Hg比(57±15)mm Hg,P=0.0001],随着年龄的增长中心动脉脉压及肱动脉脉压均有增高的趋势,但差异无统计学意义(P0.05);高血压患者中心动脉及肱动脉脉压均显著高于非高血压患者[(65±20)mm Hg比(53±14)mm Hg,P=0.004;(69±20)mm Hg比(59±13)mm Hg,P=0.013],但是中心动脉舒张压在高血压与非高血压患者间差异无统计学意义[(68±11)mm Hg比(64±11)mm Hg,P=0.132]。结论外周动脉收缩压及脉压均高于中心动脉,与年龄及是否伴高血压无关;老年组中心动脉及外周动脉脉压均显著高于非老年组;高血压患者外周动脉及中心动脉脉压高于非高血压患者,但两者中心动脉舒张压差异无统计学意义。     

住院2型糖尿病患者血压控制的影响因素

目的探讨住院2型糖尿病(type2diabetes mellitus,T2DM)患者血压控制的影响因素。方法 169例合并原发性高血压(高血压)的T2DM患者给予降压等综合治疗,以出院时血压130/80mm Hg(1mm Hg=0.133kPa)为界限分为达标组(n=97)及未达标组(n=72),比较两组入院时临床及实验室指标,并通过回归分析观察各种因素对出院时平均动脉压水平的影响。结果全组T2DM入院时收缩压为(143±15)mm Hg,舒张压为(78±8)mm Hg,控制达标率仅17.8%;出院时血压达标率57.4%,降压药物种类平均增加1种。未达标组患者入院时收缩压[(151±15)mm Hg vs.(137±12)mm Hg,P0.05)、舒张压[(80±9)mm Hg vs.(77±7)mm Hg,P0.05]均高于达标组,且血清总胆固醇浓度及24h尿白蛋白排泄率显著升高。回归分析显示,平均动脉压与入院时收缩压、舒张压、血清总胆固醇及高血压病程显著正相关,与年龄负相关;平均动脉压与尿白蛋白排泄率显著正相关(r=0.303,P0.01)。合并糖尿病肾病患者随尿白蛋白排泄率增多而收缩压显著升高,大量蛋白尿者需要多种降压药物联合治疗且血压难以控制。结论 T2DM患者门诊血压控制达标率低;住院T2DM患者血压控制受入院时血压水平、高血压病程、高胆固醇血症、高尿白蛋白排泄率等因素影响;尿白蛋白排泄率增加可能是合并糖尿病肾病患者血压难以控制的直接原因。     

高血压患者脉压与早期肾功能损害的关系

目的 通过对高血压患者不同的脉压(PP)水平与微量白蛋白尿(mAlb)之间的相关分析,探讨脉压与早期肾功能损害之间的关系.方法 根据脉压将住院确诊的130例高血压病患者分为两组,脉压＜60 mm Hg组58例,脉压≥60 mm Hg组72例.采用免疫透射比浊法测定清晨微量白蛋白尿.结果 脉压≥60 mm Hg组较脉压＜60 mm Hg组年龄、收缩压(SBP)明显增高,舒张压(DBP)明显降低(P＜0.05);脉压≥60 mm Hg组血尿酸(UA)及尿微量白蛋白明显增高.脉压与尿微量白蛋白呈正相关(r=0.243,P=0.040),血肌酐(Cr)与血尿酸呈正相关(r=0.404,P＜0.01).结论 在高血压患者中脉压是肾功能损害的危险因素之一,早期可表现为尿微量白蛋白的增加.     

腕表式动态中心动脉压记录仪在肾功能衰竭高血压患者中的应用研究

目的探讨腕表式动态中心动脉压记录仪在肾功能衰竭高血压患者中的准确性和应用价值。方法连续入选80例肾功能衰竭高血压患者,分别采用腕表式动态中心动脉压记录仪和袖带式动态血压监测仪同时监测患者24 h血压,比较两种血压监测仪24 h平均收缩压和舒张压、日间平均收缩压和舒张压、夜间平均收缩压和舒张压情况。并观察两种血压监测仪检测指标的相关性。结果袖带式动态血压监测仪和腕表式动态中心动脉压记录仪24 h平均收缩压分别为:(138.2±12.5)mm Hg和(138.3±14.5)mm Hg(1mm Hg=0.133k Pa);24 h平均舒张压分别为:(90.3±15.4)mm Hg和(89.2±16.7)mm Hg;日间平均收缩压分别为:(143.2±14.6)mm Hg和(140.2±12.3)mm Hg;夜间平均收缩压分别为:(123.3±11.5)mm Hg和(128.2±14.5)mm Hg;日间平均舒张压分别为:(88.2±14.4)mm Hg和(88.2±13.7)mm Hg;夜间平均舒张压分别为:(89.3±17.4)mm Hg和(90.3±11.7)mm Hg;两种检测方法间均无统计学差异(P均0.05)。两种动态血压监测方式指标间均高度相关(r均0.9,P均0.05)。结论腕表式动态中心动脉压记录仪和袖带式动态血压监测仪检测结果高度一致,可在临床进一步推广应用。     

老年高血压患者静息心率与左心室肥厚和肾功能的相关性

目的探讨老年原发性高血压患者静息心率与左心室肥厚(LVH)和肾功能损害的相关性。方法入选老年原发性高血压患者1766例,按静息心率水平分为3组:<70/min为A组560例、70~79/min为B组656例、>79/min为C组550例,心脏超声检查左心室结构和收缩功能,比较各组尿微量白蛋白(MAU)、24 h MAU、血肌酐、肌酐清除率等指标,采用logistic回归分析影响LVH的因素。结果 A组、B组、C组收缩压[(156.8±10.3)mm Hg vs(163.2±10.3)mm Hgvs(171.8±9.2)mm Hg,1 mm Hg=0.133 kPa]、脉压[(60.4±5.6)mm Hgvs(62.0±5.5)mm Hgvs(67.4±6.5)mm Hg]、左心室舒张末内径[(4 8.11±2.45)mm vs(49.99±2.72)mm vs(52.08±2.91)mm]、室间隔厚度[(11.07±0.76)mmvs(11.82±1.38)mmvs(12.93±1.13)mm]、左心室后壁厚度[(9.83±1.00)mm vs(10.44±1.16)mm vs(10.94±1.38)mm]、左心室质量[(162.6±29.7)gvs(159.6±24.8)gvs(179.9±24.8)g]、左心室质量指数[(102.8±8.53)g/m~2vs(107.1±7.82)g/m~2 vs(114.2±8.54)g/m~2]及LVH比例[3.04%vs 14.2%vs 33.1%]比较,差异有统计学意义(P<0.05,P<0.01)。多因素回归分析显示,静息心率是LVH的危险因素(OR=4.82,95%CI:3.46~7.83,P=0.009)。结论老年高血压患者静息心率增快与LVH和肾功能损害密切相关,可作为LVH的预测因素,并提示可能有肾功能损伤的趋势。     

平均容积保障压力支持通气治疗慢性阻塞性肺疾病急性加重期呼吸衰竭临床研究

目的探讨平均容积保障压力支持通气(AVAPS)治疗慢性阻塞性肺疾病急性加重(AECOPD)呼吸衰竭患者的疗效及其适应证。方法入选2013年10月至2015年10月入住新疆医科大学第一附属医院的120例AECOPD合并呼吸衰竭患者,随机分入不同通气组;每组再分为轻、重症组患者,观察组间血气指标和疗效指标的变化差异。结果两种模式治疗1,3和7 d时,重症患者AVAPS组与双水平气道正压通气(Bi PAP)组比较,p H值显著上升[(7.330±0.075)对(7.359±0.070),P=0.047]、[(7.334±0.061)对(7.371±0.077),P=0.023]和[(7.332±0.083)对(7.372±0.056),P=0.011],PaCO_2显著下降[(59±14)mm Hg对(48±14)mm Hg,P=0.008]、[(53±12)mm Hg对(42±13)mm Hg,P=0.003]和[(52±14)mm Hg对(38±8)mm Hg,P=0.001]。重症患者AVAPS组与Bi PAP组比较,RR、m MRC、NIV通气时间和住院天数显著降低,差异有统计学意义。结论 AVAPS模式较Bi PAP模式在治疗AECOPD呼吸衰竭重症患者显示出一定的优越性。     

老年心力衰竭患者出院时血压水平与预后的关系

目的探讨老年慢性心力衰竭(CHF)患者出院时血压水平与长期预后的关系。方法入选2010年1月~2011年12月上海市松江区中心医院心内科出院的LVEF<50%的老年CHF患者116例,随访期以心源性死亡33例作为事件组,另外83例作为非事件组。记录入院时和出院时的血压及常规检查参数,按照心力衰竭指南治疗,并进行3年随访。终点事件为心源性死亡。进行单因素Cox和多因素Cox分析。结果与非事件组比较,事件组患者出院时收缩压和舒张压降低[(108.7±10.5)/(68.5±8.4)mm Hg vs(130.3±14.2)/(74.4±10.2)mm Hg,1mm Hg=0.133kPa,P<0.01];脉压降低[(40.2±10.4)mm Hg vs(55.8±13.8)mm Hg,P<0.01]。单因素Cox分析显示,出院时收缩压<100mm Hg、脉压<45mm Hg是心源性死亡的危险因素;多因素Cox风险比例模型分析显示,出院时收缩压<100mm Hg(RR=0.918,95%CI:0.859~0.981)和N末端钠尿肽前体升高(RR=6.148,95%CI:1.841~20.532)是影响心源性死亡事件发生的主要危险因素。结论出院时收缩压<100mm Hg是老年CHF患者死亡终点的独立预测指标。     

右美托咪定对腹腔镜胆囊切除术患者应激反应及肝肾功能的影响

目的 探讨右美托咪定对腹腔镜胆囊切除术患者应激反应及肝肾功能的影响. 方法选取100例行腹腔镜下胆囊切除术的患者,根据麻醉方法分为丙泊酚组(50例)和右美托咪定组(50例),观察手术麻醉诱导血流动力学变化及应激反应,同时记录麻醉前、麻醉后及术后肝肾功能变化. 结果 插管即刻及插管后1 min丙泊酚组与有美托咪定组心率[(85.7±13.4)次/min比(62.7±9.9)次/min,t=2.296,P=0.045; (81.3±14.9)次/min比(60.3±8.8)次/min,t=2.714,P=0.022],平均动脉压[(86.3±11.9)mm Hg 比(66.5±11.7) mm Hg,t=2.653,P=0.024;(88.6±15.6) mm Hg比(68.7±12.3)mm Hg,t=2.240,P=0.049]显著升高.插管即刻、插管后1min及5 min丙泊酚组与右美托咪定组患者肾上腺素[(680.1±112.3) pmol/L比(576.1±83.1)pmol/L,t=2.628,P=0.019;(705.4±127.6) pmol/L比(648.8±105.3) pmol/L,t=2.242,P=0.039;(689.6±123.4) pmol/L比(628.2±94.3)pmol/L,t=2.224,P=0.040]、去甲肾上腺素[(3953.6±514.6) pmol/L比(3695.1±496.2) pmol/L,t=2.454,P=0.032;(4367.1±565.7) pmol/L比(3967.2±514.9)pmol/L,t=2.500,P=0.030;(4095.8±415.1) pmol/L比(3813.4±513.7) pmol/L,t=2.255,P=0.045]、皮质醇[(796.6±198.7)nmol/L比(698.7±176.3) nmol/L,t=2.334,P=0.033; (835.5±217.2) nmol/L比(783.7±201.9) nmol/L,t=2.167,P=0.044; (822.4±203.3) nmol/L比(720.6±188.1) nmol/L,t=2.189,P=0.043]比较,右美托咪定组均低于丙泊酚对照组.与麻醉前比较,两组患者肝肾功能比较差异无统计学意义(均P＞0.05). 结论 右美托咪定对腹腔镜胆囊切除术患者血流动力学更稳定,应激反应较轻,对肝肾功能无明显影响,可安全、有效地用于腹腔镜胆囊切除术.     

老年男性原发性高血压患者动态血压及血压变异性与踝臂指数的关系探讨

目的评价老年男性原发性高血压患者动态血压及血压变异性(BPV)与踝臂指数(ABI)的关系。方法入选老年男性原发性高血压患者160例,按照ABI分为正常ABI组(ABI>0.90)104例和低ABI组(ABI≤0.90)56例,比较并分析其24 h动态血压参数和BPV参数。结果低ABI组较正常ABI组24 h平均脉压[(62.4±13.8)mm Hg比(53.0±13.0)mm Hg]、日间平均脉压[(67.3±17.0)mm Hg比(55.4±20.0)mm Hg]和夜间平均脉压[(63.0±16.0)mm Hg比(52.9±13.6)mm Hg]均高(P<0.01),同时夜间收缩压最大值[(146.5±17.4)mm Hg比(135.5±17.1)mm Hg]、夜间收缩压标准差[(12.4±4.0)mm Hg比(10.1±4.2)mm Hg]均大(P<0.05)。结论老年男性原发性高血压患者夜间收缩压最大值、夜间收缩压标准差、日间平均脉压、夜间平均脉压和24 h平均脉压升高可能是低ABI的危险因素。     

丙泊酚复合雷米芬太尼靶控输注在老年肝癌患者射频消融术中的应用

目的 观察丙泊酚复合雷米芬太尼靶控输注在老年肝癌患者射频消融术中的安全性和有效性.方法 ASAⅡ-Ⅲ级的老年原发性肝癌患者30例,随机分为丙泊酚复合雷米芬太尼靶控输注组(PR组)15例和眯达唑仑复合芬太尼静脉注射组(MF组)15例,择期在有监测的麻醉处理(monitored anesthesia care,MAC)下行肝癌射频消融术.观察治疗中两组患者平均动脉压(MAP)、心率、脉搏血氧饱和度(SpO2)的变化;记录治疗中Ramsay镇静评分、患者合作评分、疼痛VAS评分,以及术后患者满意度.结果 治疗中Ramsay镇静评分、患者合作评分、疼痛VAS评分,以及术后患者满意度,PR组均优于MF组(P<0.05).MF组MAP、心率最高值[(108.7±8.6)mm Hg、(83.8±7.1)次/min]较基础值[(99.3±8.5)mm Hg、(76.3±7.1)次/min]明显增加,增加幅度显著高于PR组(P<0.05);PR组MAP、心率最低值[(84.5±6.5)mm Hg、(66.6±6.6)次/min]显著低于基础值[(97.7±6.5)mm Hg、(75.4±7.3)次/min],降低幅度高于MF组(P<0.05).两组均出现SpO2明显降低(最低值PR组95.1±2.0,MF组95.5±2.2),但两组之间差异无统计学意义(P>0.05).结论 丙泊酚复合雷米芬太尼靶控输注法更适用于老年肝癌患者射频消融术.它能保证良好的镇痛、镇静作用,但术中应注意观察患者的呼吸与血流动力学变化.     

连续肾脏替代治疗在肝移植中的应用

目的探讨连续肾脏替代治疗(CRRT)在肝移植术后急性肾功能衰竭(ARF)合并多器官功能不全(MODS)治疗中的应用价值。方法分析连续静脉静脉血液滤过(CVVH)治疗7例肝移植术后ARF、成人呼吸窘迫综合征(ARDS)、急性心衰、全身炎症反应综合征(SIRS)等患者。3例合并ARDS患者同时进行呼吸机辅助呼吸治疗。结果4例治愈,另3例ARF合并MODS患者死亡。经CVVH治疗后,患者血清中的肌酐、尿素氮、血钾较治疗前降低(P<0.05),凝血酶原时间变化无意义。结论CVVH能有效控制氮质血症和高血钾等高分解状态,而不影响凝血功能。早期应用可以改善肝移植术后ARF、ARDS、充血性心力衰竭、SIRS等MODS患者的预后。     

The challenges of providing renal replacement therapy in decompensated liver cirrhosis

Development of renal failure requiring renal replacement therapy (RRT) in the cirrhotic patient is a devastating complication. Survival without RRT is less than 10% on average at 6 months. However, it is now appreciated that all renal failure in this group of patients is not due solely to hepatorenal syndrome, and the cause of the renal failure affects the prognosis. This paper reviews the prognosis depending on cause and points out the difficulty in making the correct diagnosis. Provision of RRT is difficult in this group of patients due to hypotension and coagulopathy which is highly prevalent. Survival with RRT is still poor with only 30-60% of patients surviving to liver transplant. Provision of RRT should be offered as a bridge to patients awaiting liver transplant or those undergoing liver transplant evaluation. Provision of long-term RRT is usually not indicated in other cirrhotic patients who develop a need for RRT except as a trial to see if renal function will return. The decision between intermittent hemodialysis or continuous renal replacement therapy (CRRT) is usually based on the clinical characteristics of the patient. Neither has been demonstrated to be superior to the other, although CRRT may be better tolerated in the unstable patient. CRRT is clearly indicated in cases of fulminant hepatic failure as it does not raise intracranial pressure. Provision of intraoperative CRRT during liver transplant may be indicated to help control volume and electrolytes in those patients presenting for liver transplant with renal failure. Newer extracorporeal support systems, such as extracorporeal albumin dialysis (MARS) and fractional plasma separation and adsorption with hemodialysis (Prometheus), have recently been developed to provide both renal and liver support in this group of patients. These are still considered experimental, although the MARS system has been utilized to treat patients with hepatorenal syndrome, and is available outside the United States.     

连续肾脏替代治疗对肝移植术后感染的治疗作用

目的探讨连续性肾脏替代治疗（CRRT）对肝移植感染急性肾功能衰竭的治疗作用。方法回顾性分析36例肝移植术后感染的病例，其中急性肾功能衰竭24例，15例接受了CRRT治疗，观察其死亡率、治疗前后生命体征、血流动力学、血电解质和酸碱平衡、肝、肾功能变化和副作用。结果CRRT能降低肝移植感染急性肾功能衰竭死亡相对危险度（RR=1．00，95％CI0．02～50．40），改善患者生命体征和血流动力学（P〈0．05），纠正电解质和酸碱平衡紊乱（P〈0．05），改善肝、肾功能（P〈0．05），治疗过程中，副作用少，患者耐受性好。结论CRRT可望成为肝移植感染急性肾功能衰竭的有效治疗方法之一。     

Continuous arteriovenous hemodialysis and continuous venovenous hemofiltration in burn patients with acute renal failure

Acute renal failure (ARF) is a very common condition that may occur in patients with major burn injuries. The majority of burn patients with ARF have a high mortality rate, ranging from 73% to 100%. There are several ways to treat ARF in burn patients, including peritoneal dialysis (PD), intermittent hemodialysis, and continuous renal replacement therapy (CRRT). CRRT is generally used in patients in whom intermittent hemodialysis has failed to control hypovolemia, as well as in patients who cannot tolerate intermittent hemodialysis. Additionally, PD is not suitable for patients with burns within the abdominal area. For these reasons, most patients with unstable hemodynamic conditions receive CRRT. In this study (conducted in our burn unit between 1997 and 2004), six burn patients received CRRT: three received continuous arteriovenous hemodialysis (CAVHD) and the other three received continuous venovenous hemofiltration (CVVH). The patients were all males, with a mean age of 49.8 years (range, 27-80 years), and a mean burnt surface area of 65.1% (range, 30-95%). Four patients died due to multiple organ failure, and two patients recovered from severe ARF. CRRT has been proven safe and useful for burn patients with ARF. According to this study, we conclude that CVVH is an appropriate tool for treating ARF, with a lower incidence of vascular complications than CAVHD.     

End-stage renal failure patients requiring renal replacement therapy in the intensive care unit: incidence,clinical features,and outcome

AIMS: To study incidence, clinical features, and outcome of critically ill patients with end-stage renal failure (ESRF) requiring renal replacement therapy (RRT) in the intensive care unit (ICU) and to test the validity of severity scoring systems for these patients. METHODS: Data for ESRF patients treated with RRT were collected from 81 Australian adult ICUs providing RRT. They were compared with matched controls with acute renal failure. RESULTS: Thirty-eight ESRF patients received RRT in the ICU over 3 months. The mean APACHE II score was 21.8 (predicted mortality: 37%) and the SAPS II score 44.7 (predicted mortality: 37%). The hospital mortality was 34%. Receiver operating characteristic curves showed good discrimination ability for hospital mortality for these two scores (AUC: 0.81 for APACHE II and 0.84 for SAPS II). Using admission diagnosis and SAPS II scores, 32 ESRF patients treated with continuous RRT (CRRT) were matched to 32 acute renal failure patients also treated with CRRT. ICU mortality (22 vs. 38%) and hospital mortality (38 vs. 38%) were comparable between the two groups. CONCLUSIONS: ESRF patients requiring RRT in the ICU were relatively frequent. Severity scores could be used to predict the hospital outcome for these patients. Their mortality, when treated with CRRT, was similar to that of diagnosis- and severity-score-matched patients with acute renal failure.     

连续性肾脏替代治疗在心内直视术后急性肾功能衰竭的应用

目的总结连续性肾脏替代疗法（CRRT）治疗心内直视术后急性肾功能衰竭（ARF）的经验。方法1999年1月至2005年5月共发生51例心内直视术后急性肾功能衰竭患者,均采用CRRT进行治疗。结果存活的30例患者在CRRT治疗12 h后血气和电解质明显改善,18288 h进入多尿期,肾功能逐渐恢复正常。死亡的21例患者中早期5例治疗偏晚,肾功能未恢复,最终肾衰死亡,另16例CRRT治疗1周后肾功能均恢复,但因低心排、感染及呼吸循环衰竭等非肾性因素死亡。结论CRRT是救治心内直视术后并发ARF的有效手段。     

连续性肾脏替代疗法在重症急性肾功能衰竭治疗中的应用

目的 回顾分析连续性肾脏替代疗法（ＣＲＲＴ）在重症急性肾功能衰竭（ＡＲＦ）治疗中的应用和影响预后的因素。方法 １９８６年５月至１９９９年１月用ＣＲＲＴ治疗重症ＡＲＦ患者１０１例,回顾性分析了患者临床特点、ＣＲＲＴ方法和预后。结果 １０１例患者中６０例（５９．４％）度过疾病的急性期（存活组）,４１例（４０．６％）在急性期死亡（死亡组）,对两组患者的临床统计学资料、肾功能衰竭的特点、疾病严重程度（ＡＰ     

连续性血液净化在ICU多器官功能障碍综合征合并急性肾衰竭患者的应用及预后分析

目的探讨连续性血液净化治疗（CBPT）在ICU多器官功能障碍综合征（MODS）合并急性肾衰竭（APF）患者的疗效及影响预后的相关因素。方法回顾性分析2004年1月至2008年2月该院ICU中行连续性静-静脉血液滤过（CVVH）治疗的245例MODS合并ARF患者一般资料、血液生化检查、疾病严重程度评分等，对比分析CVVH治疗前后临床参数的变化及影响预后的因素。结果CVVH对容量负荷、溶质清除效果明显；反映疾病严重程度如氧合指数、APACHEⅡ评分、MODS评分、SOFA评分CVVH治疗前后比较无明显差异；全部患者死亡率为64．9％，病死率随着衰竭器官数目的增加而显著升高。多因素回归分析显示，患者CVVH治疗前衰竭器官数、医院获得性ARF、CVVH前APACHEⅡ评分、平均动脉压是独立危险因素。结论对于MODS合并ARF患者，CVVH治疗前患者疾病的严重程度是影响预后的重要因素，依据患者临床病情早期积极CBPT可能改善MODS合并ARF患者的预后。     

Predictors of mortality in a cohort of intensive care unit patients with acute renal failure receiving continuous renal replacement therapy

BACKGROUND: Despite the frequent use of continuous renal replacement therapy (CRRT) in the management of acute renal failure (ARF) in the critically ill, predictors of mortality remain unclear. METHODS: A registry of all patients initiated on CRRT at a single institution was assembled over an 18-month period, and a subsequent cross-sectional analysis of selected variables was conducted for associations with mortality. Predictors evaluated were age, gender, diagnosis of sepsis, Apache II score, days between ARF diagnosis and initiation of CRRT, creatinine at initiation of CRRT, change in creatinine from baseline and admission to initiation of CRRT, setting of ARF, and prescribed CRRT dose. The principal outcome was mortality at 30 days. RESULTS: Eighty-one individuals met inclusion criteria. Overall mortality for the study was 50.2%. The mean elevation in creatinine from admission to initiation of CRRT was 1.6 mg/dL (141.4 micromol/L) in those who lived and 2.6 mg/dL (229.8 micromol/L) in those who died (P = 0.023). Patients admitted with normal renal function who developed ARF while in the hospital had mortality of 56.3%. When available, patients with abnormal renal function at presentation were further classified by either abnormal or normal preadmission creatinine. These patients had mortality of 31.3% and 83.3%, respectively. These differences in mortality were statistically significant. CONCLUSIONS: Increased mortality was significantly associated with the magnitude of change in serum creatinine between admission and initiation of CRRT. Also, patient ARF classification was significantly associated with mortality.